Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone acetate, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; macrogol 3350; miripirium chloride; sodium chloride; sodium hydroxide - indications as at 17 november 2004: a.for intramuscular administration. when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-nisolone is indicated as follows: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia. hypercalcaemia associated with cancer. non-suppurative thyroiditis. 2. rheumatic disorders. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. epicondylitis. synovitis of osteoarthritis. acute non-specific tenosynovitis. rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). acute gouty arthritis. psoriatic arthritis. ankylosing spondylitis. acute and subacute bursitis. 3. collagen diseases. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus. acute rheumatic carditis. systemic dermatomyositis (polymyositis). 4. dermatological diseases. pemphigus. bullous dermatitis herpetiformis. severe erythema multiforme (stevens-johnson syndrome). severe seborrhoeic dermatitis. exfoliative dermatitis. severe psoriasis. mycosis fungoides. 5. allergic states. control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: bronchial asthma. drug hypersensitivity reactions. contact dermatitis.urticarial transfusion reactions. atopic dermatitis. acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). serum sickness. 6. ophthalmic diseases. severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus. sympathetic ophthalmia. iritis, iridocyclitis. anterior segment inflammation. chorioretinitis. allergic conjunctivitis. diffuse posterior uveitis. allergic corneal marginal ulcers. optic neuritis. keratitis. 7. gastrointestinal diseases. to tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy). regional enteritis (systemic therapy). 8. respiratory diseases.symptomatic sarcoidosis. berylliosis. fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. aspiration pneumonitis. loeffler's syndrome not manageable by other means. 9. haematological disorders. acquired (autoimmune) haemolytic anaemia. erythroblastopenia (rbc anaemia). secondary thrombocytopenia in adults. congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases. for palliative management of: leukaemias and lymphomas in adults. acute leukaemia in childhood. 11. oedematous states. to induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous. tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. trichinosis with neurological or myocardial involvement. b. for intra-articular or soft tissue administration depo-nisolone is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis. epicondylitis. rheumatoid arthritis. acute non-specific tenosynovitis. acute and subacute bursitis. post-traumatic osteoarthritis. acute gouty arthritis. c. for intralesional administration. depo-nisolone is indicated for intralesional use in the following conditions: keloids.discoid lupus erythematosus. necrobiosis lipoidica diabeticorum. alopecia areata. localised hypertrophic, infiltrated inflammatory lesions of licen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis). depo-nisolone may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 1 mg/g - paste - excipient ingredients: gelatin; pectin; carmellose sodium; polyethylene; liquid paraffin - acute and chronic lesions of the oral mucosa including recurrent ulcerative aphthous stomatitis; erosive lichen planus; denture stomatitis; traumatic lesions including denture sore spots; desquamative gingivitis and stomatitis. lesions of traumatic origin and most nonrecurring conditions heal rapidly and permanently. chronic and recurrent lesions are promptly relieved, but symptoms usually recur after termination of therapy. however, kenalog in orabase is effective in suppressing subsequent recurrences.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; gelatin; magnesium stearate; caramel; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified water; industrial methylated spirit; ammonia - indications as at 19 december 2000: treatment of ulcerative colitis in patients intolerant of sulphasalazine.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - ranitidine hydrochloride - oral powder, pre-mix - ranitidine hydrochloride furan active 1000.0 mg/g - miscellaneous veterinary - horse | horse foal | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare - gastric ulcers | heal/reduce gastric ulceration

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - testosterone enanthate - parenteral liquid/solution/suspension - testosterone enanthate steroid-anabolic active 75.0 mg - endocrine system - sheep wether (castrated male) | castrated male | ovine - external preputial ulceration | sheath rot

Israel - English - Ministry of Health

taro international ltd, israel - triamcinolone acetonide - paste - triamcinolone acetonide 0.1 % - triamcinolone - triamcinolone - indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - lidocaine hydrochloride monohydrate; triamcinolone acetonide - paste - lidocaine hydrochloride monohydrate 3 g / 100 g; triamcinolone acetonide 0.1 g / 100 g - triamcinolone - triamcinolone - adjunctive treatment and temporary relief of pain and symptoms associated with oral inflammatory and ulcerative lesions.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets enteric coated - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - for active rheumatoid arthritis which is not controlled by antiinflammatory drugs.ulcerative colitis, crohn's disease, pyoderma gangrenosum.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - treatment of ulcerative colitis and crohn's disease.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - enema - mesalazine 4 g / 60 g - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.